Real-world Clinical Outcomes in Patients Receiving Zotarolimus-eluting Stents versus Non-zotarolimus-eluting Stents for Percutaneous Coronary Intervention
Authors:
- Jonathan Ong Wei ShengJSJonathan Ong Wei Sheng
- Muhammad Bin Idu JionMJMuhammad Bin Idu Jion
- Keh Yann ShanKSKeh Yann Shan
- Marawan Saber Attia ElkaramanyMEMarawan Saber Attia Elkaramany
- Gao FeiGFGao Fei
- Ningyan WongNWNingyan Wong
- Jonathan Jiunn Liang YapJYJonathan Jiunn Liang Yap
- Chin Chee YangCYChin Chee Yang
- Jiang Ming FamJFJiang Ming Fam
- Kay Woon HoKHKay Woon Ho
- Khung Keong YeoKYKhung Keong Yeo
Open Access
- 18 March 2025
- journal article
- Published by Radcliffe Medical Media Ltd in Journal of Asian Pacific Society of Cardiology
- Vol. 4
Abstract
Background: Current-generation zotarolimus-eluting stents (ZES) have been shown to be an effective choice for percutaneous coronary intervention. However, data comparing real-world clinical outcomes between ZES and other stent platforms (non-ZES) are limited. We aim to compare real-world clinical outcomes of patients receiving ZES versus non-ZES during percutaneous coronary intervention based on our centre’s registry. Methods: This was a non-randomised, non-blinded, all-comers observational registry comparing clinical outcomes in patients treated with ZES versus non-ZES (control). The primary endpoint of our study was defined as major adverse cardiac events, which was a composite of cardiac mortality, target vessel failure and MI at 1 year. Results: Within the study period, 526 patients fulfilled inclusion criteria (ZES: 218, controls: 308). Characteristics and procedural data of both groups were similar. Our study showed no significant differences in major adverse cardiac events between the ZES and control groups (3.2% versus 3.9%; HR 0.82; 95% CI [0.32–2.09]; p=0.68). Comparing clinical outcomes of ZES and control groups, there were similar rates of all-cause mortality (1.4% versus 2.3%; HR 0.60; 95% CI [0.16–2.33]; p=0.46) and MI (0.5% versus 1.0%; HR 0.47; 95% CI [0.049–4.49]; p=0.51). There were low rates of stent-related complications and no differences in target vessel revascularisation (1.4% versus 0.7%; HR 2.12; 95% CI [0.36–12.7]; p=0.41) and target vessel failure (1.4% versus 0.7%; HR 2.12; 95% CI [0.36–12.7]; p=0.41) between the ZES and control groups. Conclusion: Our study showed no significant differences in clinical outcomes between patients receiving ZES and those receiving non-ZES.Keywords
This publication has 8 references indexed in Scilit:
- A large, prospective, multicentre study of left main PCI using a latest-generation zotarolimus-eluting stent: the ROLEX studyEuroIntervention, 2023
- Amphilimus- vs. zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: the SUGAR trialEuropean Heart Journal, 2021
- Real-World Three-Year Clinical Outcomes of Biolimus-Eluting Stents versus Other Contemporary Drug-Eluting Stents in Patients with Acute Myocardial Infarction Patients: Data from the Korea Acute Myocardial Infarction Registry (KAMIR)Journal of Interventional Cardiology, 2021
- Polymer-based or Polymer-free Stents in Patients at High Bleeding RiskNew England Journal of Medicine, 2020
- Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt–chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, randomised non-inferiority trialThe Lancet, 2018
- One-year clinical outcomes of patients implanted with a Resolute Onyx™ zotarolimus-eluting stentJournal of International Medical Research, 2017
- A Randomized Controlled Trial in Second-Generation Zotarolimus-Eluting Resolute Stents Versus Everolimus-Eluting Xience V Stents in Real-World PatientsJACC, 2012
- Comparison of Zotarolimus-Eluting and Everolimus-Eluting Coronary StentsNew England Journal of Medicine, 2010